| Literature DB >> 27374009 |
Chaojie Yang1, Peng Li1, Xiujuan Zhang2, Qiuxia Ma1, Xianyan Cui1, Hao Li1, Hongbo Liu1, Jian Wang1, Jing Xie1, Fuli Wu1, Chunyu Sheng1, Xinying Du1, Lihua Qi1, Wenli Su1, Leili Jia1, Xuebin Xu3, Jiayong Zhao4, Shengli Xia4, Na Zhou5, Hui Ma5, Shaofu Qiu1, Hongbin Song1.
Abstract
To conduct the first comprehensive analysis of Shigella flexneri serotype 4s, a novel serotype found in 2010, we identified 24 serotype 4s isolates from 1973 shigellosis cases in China (2002-2014). The isolates were characterized by single nucleotide polymorphism (SNP) phylogenetic analysis, pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST) to determine their genetic relatedness, and analysed further for their antimicrobial susceptibilities and antimicrobial resistance determinants. The PFGE and SNP phylogenetic analyses suggest that S. flexneri serotype 4s strains are derived from multiple serotypes, including two predominant serotypes in China: serotype X variant and serotype II. Three new sequence types were identified by MLST. All isolates were resistant to ticarcillin, ampicillin and tetracycline, with high-level resistance to third-generation cephalosporins. Notably, all the isolates were multidrug resistant (MDR), with the highest levels of resistance observed for eight antimicrobials classes. Most isolates contain various antimicrobial resistance determinants. In conclusion, we found that serotype 4s isolates have multiple evolutionary sources, diverse biochemical characteristics and genomes, and highly prevalent multidrug resistance and antimicrobial-resistant determinants. With few clinical treatment options, continuous monitoring and timely intervention against this emerging MDR serotype is essential. The possibility that serotype 4s will become the next predominant serotype exists.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27374009 PMCID: PMC4931504 DOI: 10.1038/srep29124
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Biochemical characteristics of S. flexneri serotype 4s isolates.
| No. | Biochemical characteristics | ||||||
|---|---|---|---|---|---|---|---|
| IND | GLU | MAN | SOR | MEL | ARA | others* | |
| BJ4s01 | − | + | + | − | + | + | − |
| BJ4s02 | − | + | + | − | + | + | − |
| BJ4s03 | − | + | + | − | + | + | − |
| BJ4s04 | − | + | + | − | + | + | − |
| BJ4s05 | − | + | + | − | + | + | − |
| GX4s01 | + | + | + | − | + | + | − |
| GX4s02 | + | + | + | − | + | + | − |
| GX4s03 | − | + | + | − | + | + | − |
| GX4s04 | − | + | + | − | + | + | − |
| GX4s05 | + | + | + | − | + | + | − |
| HN4s01 | − | + | + | − | + | + | − |
| HN4s02 | − | + | + | − | + | + | − |
| HN4s03 | − | + | + | − | + | + | − |
| HN4s04 | − | + | + | − | + | + | − |
| HN4s05 | − | + | + | − | + | + | − |
| HN4s06 | − | + | + | − | + | + | − |
| SH4s01 | + | + | + | + | − | + | − |
| SH4s02 | − | + | + | − | + | + | − |
| SH4s04 | − | + | + | − | − | + | − |
| SH4s05 | + | + | + | − | + | + | − |
| SH4s06 | + | + | + | − | + | + | − |
| SH4s07 | − | + | + | − | + | + | − |
| SH4s08 | + | + | + | − | + | + | − |
| SH4s09 | − | + | + | − | + | + | − |
IND, indole; GLU, glucose; MAN, mannitol; SOR, sorbitol; MEL, melibiose; ARA, arabinose. “others*” includes: o-nitrophenyl-β-D-galactopyranoside, arginine dihydrolase, lysine decarboxylase, ornithine decarboxylase, citrate utilization, H2S, urease, rhamnose, tryptophane deaminase, acetoin, gelatinase, inositol, sucrose, amygdalin.
Figure 1PFGE profiles, antimicrobial susceptibility profiles and sequence types (STs) of Shigella flexneri serotype 4s, 2 and xv isolates.
The serotype, origin, strain number, year of isolation and ST are listed after each PFGE profile. AMK, amikacin; AMP, ampicillin; ATM, aztreonam; CHL, chloramphenicol; CAZ, ceftazidime; CFP, cefoperazone; CFZ, cefazolin; CRO, ceftriaxone; FEP, cefepime; FOX, cefoxitin; GEN, gentamicin; IPM, imipenem; LVX, levofloxacin; NIT, nitrofurantoin; NOR, norfloxacin; PIP, piperacillin; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline; TIC, ticarcillin; TIM, ticarcillin/clavulanic acid constant 2; TOB, tobramycin. Black indicates “resistant”, grey indicates “intermediate susceptibility” and blank indicates “sensitive”. Stars represent 4s strains whose PFGE patterns are identical. Four cornered stars represent 4s strains whose PFGE patterns are very different from the others. Diamonds represent 4s strains with new MLST types. Triangles represent 4s strains with resistance to at least 7 antibiotic classes.
Figure 2Phylogenetic analysis of Shigella flexneri serotype 4s and other S flexneri serotypes.
The maximum likelihood tree is generated from core SNPs using kSNP56 for the 24 S. flexneri 4s strains sequenced, 4 standard strains of S. flexneri and 35 strains from the Shigella Genome Sequencing Consortium collection14. The 24 S. flexneri 4s strains are highlighted by black circles. The names of the 35 strains are composited by their origin number, phylogenetic group number and S. flexneri serotype.
Figure 3Antimicrobial resistance pattern for Shigella flexneri serotype 4s.
The classifications “WHO Category Level” and “Importance” are based on the classification determined at the 2011 WHO (World Health Organization) meeting in Oslo, Norway20. The antimicrobial agents were categorized as critically important, highly important or important based on two criteria: (1) their use as sole therapy or one of the few alternatives to treat serious human disease, and (2) their use to treat disease caused by organisms that may be transmitted via non-human sources or diseases caused by organisms that may acquire resistance genes from non-human sources. Antimicrobial agents are considered critically important if both criteria (1 and 2) are applicable. Antimicrobial agents are highly important if criterion 1 or 2 is applicable. Antimicrobial agents are important if neither criterion is applicable. TIC/CLA 2*: ticarcillin/clavulanic acid constant 2; TRI/SUL*: trimethoprim/sulfamethoxazole.
Multidrug resistance profiles of S. flexneri serotype 4s isolates (n = 24).
| Antimicrobial resistance profiles | Antimicrobial kinds quantity | Isolates quantity | Antimicrobial classes | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminog-lycosides | Cephalo-sporins | Penicillins | Quinolones | Monobactams | Amphenicols | Cephamycins | Folate pathway inhibitors | Tetracyclines | |||
| TIC/AMP/TET/CHL | 4 | 7 | + | + | + | ||||||
| TIC/AMP/TET/CHL/SXT | 5 | 6 | + | + | + | + | |||||
| TIC/AMP/TET/CHL/CFZ/FOX | 6 | 1 | + | + | + | + | |||||
| TIC/AMP/NOR/TET/CHL/SXT | 6 | 1 | + | + | + | + | + | ||||
| TOB/GEN/PIP/TIC/AMP/TET/SXT | 7 | 1 | + | + | + | + | |||||
| TIM/CRO/CFP/PIP/TIC/AMP/TET/CHL/CFZ | 9 | 1 | + | + | + | + | + | ||||
| TIM/CRO/CFP/PIP/TIC/AMP/TET/CHL/CFZ/SXT | 10 | 2 | + | + | + | + | + | + | |||
| GEN/CRO/CFP/PIP/TIC/AMP/TET/CHL/CFZ/SXT | 10 | 1 | + | + | + | + | + | + | + | ||
| GEN/CRO/CFP/PIP/TIC/AMP/TET/CHL/CFZ/SXT/ATM | 11 | 1 | + | + | + | + | + | + | + | + | |
| CAZ/CRO/CFP/PIP/TIC/AMP/TET/CHL/CFZ/SXT/ATM | 11 | 1 | + | + | + | + | + | + | + | ||
| CRO/CFP/PIP/TIC/AMP/LVX/NOR/TET/CHL/CFZ/SXT | 11 | 1 | + | + | + | + | + | + | + | ||
| TOB/GEN/CRO/TIC/AMP/LVX/NOR/TET/CHL/CFZ/SXT | 11 | 1 | + | + | + | + | + | + | + | + | |
Antimicrobial resistance determinants of S. flexneri serotype 4s isolates.
| No. | β-Lactamases gene and type | QRDR (or outside) mutation | PMQR gene | Integrons and gene cassette array | |||||
|---|---|---|---|---|---|---|---|---|---|
| BJ4s01 | + | + | − | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | |
| BJ4s02 | + | + | − | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | |
| BJ4s03 | + | + | − | S83L, H211Y | S80I | + | − | dfrA1 + sat1 + aadA1 | |
| BJ4s04 | + | + | − | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | |
| BJ4s05 | + | + | − | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | |
| GX4s01 | + | + | S83L, H211Y | S80I | + | − | dfrA1 + sat1 + aadA1 | ||
| GX4s02 | + | + | − | S83L, H211Y | S80I | - | − | dfrA1 + sat1 + aadA1 | |
| GX4s03 | + | + | − | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | |
| GX4s04 | + | + | − | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | |
| GX4s05 | + | + | − | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | |
| HN4s01 | + | + | − | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | |
| HN4s02 | + | + | S83L, H211Y | S80I | − | − | dfrA17 + aadA5 | dfrA1 + sat1 + aadA1 | |
| HN4s03 | + | + | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | ||
| HN4s04 | + | + | − | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | |
| HN4s05 | + | + | − | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | |
| HN4s06 | + | + | S83L, H211Y | S80I | + | + | aacA4 + cmlA1 | dfrA1 + sat1 + aadA1 | |
| SH4s01 | + | + | − | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | |
| SH4s02 | + | + | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | ||
| SH4s04 | + | + | − | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | |
| SH4s05 | + | + | − | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | |
| SH4s06 | + | + | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | ||
| SH4s07 | + | + | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | ||
| SH4s08 | + | + | − | S83L, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | |
| SH4s09 | + | + | − | S83L, S87N, H211Y | S80I | − | − | dfrA1 + sat1 + aadA1 | |